Market closed
Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
Ticker
$GILD
Sector
NON_CLASSIFIED
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Foster city, United States
Employees
18,000
Website
Gilead Sciences Metrics
BasicAdvanced
$80B
178.73
$0.36
0.22
$3.02
4.79%
Price and volume
Market cap
$80B
Beta
0.22
52-week high
$87.87
52-week low
$62.07
Average daily volume
148M
Dividend rate
$3.02
Financial strength
Current ratio
1.079
Quick ratio
0.936
Long term debt to equity
122.738
Total debt to equity
143.646
Dividend payout ratio (TTM)
792.77%
Interest coverage (TTM)
13.67%
Management effectiveness
Return on assets (TTM)
0.77%
Return on equity (TTM)
2.51%
Return on investment (TTM)
0.96%
Valuation
Price to earnings (TTM)
178.731
Price to revenue (TTM)
2.917
Price to book
4.566
Price to free cash flow (TTM)
19.669
Five year average dividend yield
3.86%
Dividend yield (TTM)
4.70%
Forward dividend yield
4.79%
Growth
Revenue change (TTM)
1.51%
Earnings per share change (TTM)
-91.87%
3-year revenue growth (CAGR)
3.17%
3-year earnings per share growth (CAGR)
258.92%
3-year dividend per share growth (CAGR)
3.32%
What the Analysts think about Gilead Sciences
Analyst Ratings
Majority rating from 32 analysts.
Gilead Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.7B
-6.02%
Net income
-$4.2B
-392.09%
Profit margin
-62.38%
-410.81%
Gilead Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.34
$2.29
$1.72
-$1.32
-
Expected
$1.64
$1.92
$1.76
-$1.49
$1.59
Surprise
18.42%
19.44%
2.24%
11.59%
-
Gilead Sciences News
AllArticlesVideos
Stocks on the Move: Merck, Gilead Sciences, P&G, PG&E Corp, Adobe and the URNM
CNBC Television·6 hours ago
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Reuters·3 days ago
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $80B as of April 24, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 178.73 as of April 24, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of April 24, 2025, the dividend rate is $3.02 and the yield is 4.79%. Gilead Sciences has a payout ratio of 792.77% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment date is unconfirmed.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.